Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Meyer

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
British Journal of Clinical Pharmacology|August 25, 2015
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compoundsAmit A Somani, Kirstin Thelen, Songmao Zheng, et al.
Clinical Pharmacology and Therapeutics|July 16, 2022
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated AnalysisMaria E Trujillo, Leticia Arrington, Yogesh Patel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 5, 2023
Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for VericiguatSebastian Frechen, Ibrahim Ince, André Dallmann, et al.
Pediatric Pulmonology|December 12, 2022
Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertensionStefan Willmann, Andrea Kerstin Keller, Michaela Meyer, et al.
Scientific Reports|December 31, 2024
Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF studyMarat Fudim, Muhammad Shahzeb Khan, Dominik Linz, et al.
Journal of Clinical Pharmacology|June 29, 2021
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in ChildrenIbrahim Ince, André Dallmann, Sebastian Frechen, et al.
American Heart Journal|April 28, 2023
Electronic health record characterization and outcomes of heart failure with preserved ejection fractionVishal N Rao, Derek D Cyr, Lisa M Wruck, et al.
The Science of the Total Environment|August 31, 2015
Relevance of canopy drip for the accumulation of nitrogen in moss used as biomonitors for atmospheric nitrogen deposition in EuropeMichaela Meyer, Winfried Schröder, Stefan Nickel, et al.
Frontiers in Physiology|April 13, 2011
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networksThomas Eissing, Lars Kuepfer, Corina Becker, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
British Journal of Clinical Pharmacology|August 25, 2015
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compoundsAmit A Somani, Kirstin Thelen, Songmao Zheng, et al.
Clinical Pharmacology and Therapeutics|July 16, 2022
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated AnalysisMaria E Trujillo, Leticia Arrington, Yogesh Patel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 5, 2023
Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for VericiguatSebastian Frechen, Ibrahim Ince, André Dallmann, et al.
Pediatric Pulmonology|December 12, 2022
Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertensionStefan Willmann, Andrea Kerstin Keller, Michaela Meyer, et al.
Scientific Reports|December 31, 2024
Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF studyMarat Fudim, Muhammad Shahzeb Khan, Dominik Linz, et al.
Journal of Clinical Pharmacology|June 29, 2021
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in ChildrenIbrahim Ince, André Dallmann, Sebastian Frechen, et al.
American Heart Journal|April 28, 2023
Electronic health record characterization and outcomes of heart failure with preserved ejection fractionVishal N Rao, Derek D Cyr, Lisa M Wruck, et al.
The Science of the Total Environment|August 31, 2015
Relevance of canopy drip for the accumulation of nitrogen in moss used as biomonitors for atmospheric nitrogen deposition in EuropeMichaela Meyer, Winfried Schröder, Stefan Nickel, et al.
Frontiers in Physiology|April 13, 2011
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networksThomas Eissing, Lars Kuepfer, Corina Becker, et al.
Pageof 4